NxStage Medical (NXTM) : NxStage Medical (NXTM) had a healthy money flow of $1.11 million into the stock during the Thursdays trading session. The value of bullish trades on upticks was $2 million, whereas, investors only sold shares worth $0.89 million on downticks. The stock closed the day with an up-down ratio of 2.24.The money flow in the block trades to the tune of $1.1 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $1.1 million worth of transactions were on upticks. NxStage Medical (NXTM) stock slid $0.49 intraday and traded at 21.72, a change of -2.21% over previous days close. However, for the week, the company shares are -5.19% compared to previous weeks close.
The stock has recorded a 20-day Moving Average of 4.7% and the 50-Day Moving Average is 12.18%. Shares have rallied 55.05% from its 1 Year high price. On Jul 8, 2016, the shares registered one year high at $23.08 and the one year low was seen on Jul 28, 2015. The 50-Day Moving Average price is $20.26 and the 200 Day Moving Average price is recorded at $17.67.
NxStage Medical (NASDAQ:NXTM): The stock opened at $22.24 on Thursday but the bulls could not build on the opening and the stock topped out at $22.42 for the day. The stock traded down to $21.66 during the day, due to lack of any buying support eventually closed down at $21.97 with a loss of -1.08% for the day. The stock had closed at $22.21 on the previous day. The total traded volume was 545,503 shares.
In an insider trading activity, The Securities and Exchange Commission has divulged that Turk Joseph E Jr, (President) of Nxstage Medical, Inc., had unloaded 1,500 shares at an average price of $17.89 in a transaction dated on May 12, 2016. The total value of the transaction was worth $26,835.
NxStage Medical, Inc. is a medical device company. The Company is engaged in the development, manufacturing and marketing of products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Companys products include the System One, Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles. Its primary product, the System One, is a small, portable, easy-to-use hemodialysis system. It is designed to deliver the therapeutic flexibility and clinical benefits associated with traditional dialysis machines in a smaller, portable, easy-to-use form that can be used by healthcare professionals and trained lay users alike in a variety of settings, including patient homes, as well as more traditional care settings such as hospitals and dialysis centers. The Company operates in three reportable business segments: System One, In-Center and Services.